European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Provided By PR Newswire
Last update: Feb 14, 2025
- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials
Read more at prnewswire.com12.73
+0.91 (+7.7%)
Find more stocks in the Stock Screener
ARCT Latest News and Analysis
17 days ago - ChartmillWhich stocks are moving before the opening bell on Tuesday?Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
18 days ago - ChartmillWhich stocks are moving after the closing bell on Monday?The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
